![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 31, 2026
An update on our NCTN grant award, practice-changing multiple myeloma research, a promising new lung cancer study, and highlights from the Comis Translational Science Symposium
July 31, 2026
This trial is evaluating a new immunotherapy approach for patients with high-risk multiple myeloma that has returned after initial treatment
July 31, 2026
ECOG-ACRIN’s Trial Results Summaries Project informs clinical trial participants of study findings, recognizes their vital contributions, and fosters a spirit of partnership in cancer research
July 31, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
July 31, 2026
The latest findings in breast cancer, cardiotoxicity, leukemia, lung cancer, myeloma, NCI-MATCH, and smoking cessation support during cancer treatment
July 31, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
June 29, 2026
An update on federal funding and policy developments shaping the future of cancer research
July 16, 2026
This trial is testing an immune-based treatment combination (teclistamab and pomalidomide) for patients with multiple myeloma that has come back early
June 29, 2026
This study is using PET imaging to guide treatment for prostate cancer recurrence
June 29, 2026
The latest findings in brain tumors, breast cancer, kidney cancer, lung cancer, Merkel cell carcinoma, and precision oncology
June 29, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
May 28, 2026
A recap of the Spring 2026 Group Meeting and reflections on addressing distrust in science